Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration

NCT00531024 is registered in ClinicalTrials.gov with The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery as lead sponsor.

NCT NCT00531024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00531024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Systemic Bevacizumab (Avastin) Therapy for Exudative Neovascular Age-Related Macular Degeneration
Lead sponsor
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2005
Completion date
March 31, 2008
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration